Derivation of a triple mosaic adenovirus for cancer gene therapy.
A safe and efficacious cancer medicine is necessary due to the increasing population of cancer patients whose particular diseases cannot be cured by the currently available treatment. Adenoviral (Ad) vectors represent a promising therapeutic medicine for human cancer therapy. However, several improvements are needed in order for Ad vectors to be effective cancer therapeutics, which include, but are not limited to, improvement of cellular uptake, enhanced cancer cell killing activity, and the capability of vector visualization and tracking once injected into the patients. To this end, we attempted to develop an Ad as a multifunctional platform incorporating targeting, imaging, and therapeutic motifs. In this study, we explored the utility of this proposed platform by generating an Ad vector containing the poly-lysine (pK), the herpes simplex virus type 1 (HSV-1) thymidine kinase (TK), and the monomeric red fluorescent protein (mRFP1) as targeting, tumor cell killing, and imaging motifs, respectively. Our study herein demonstrates the generation of the triple mosaic Ad vector with pK, HSV-1 TK, and mRFP1 at the carboxyl termini of Ad minor capsid protein IX (pIX). In addition, the functionalities of pK, HSV-1 TK, and mRFP1 proteins on the Ad vector were retained as confirmed by corresponding functional assays, indicating the potential multifunctional application of this new Ad vector for cancer gene therapy. The validation of the triple mosaic Ad vectors also argues for the ability of pIX modification as a base for the development of multifunctional Ad vectors.
Tang
Yizhe
Y
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Wu
Hongju
H
Ugai
Hideyo
H
Matthews
Qiana L
QL
Curiel
David T
DT
D000256:Adenoviridae / Q000235:genetics* / Q000648:ultrastructure; D000257:Adenoviridae Infections / Q000235:genetics; D015153:Blotting, Western; D002213:Capsid / Q000378:metabolism; D036022:Capsid Proteins / Q000378:metabolism; D016923:Cell Death; D002460:Cell Line; D004274:DNA, Recombinant / Q000235:genetics; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D008164:Luminescent Proteins / Q000378:metabolism; D008856:Microscopy, Fluorescence; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D011107:Polylysine / Q000378:metabolism; D013499:Surface Properties; D013937:Thymidine Kinase / Q000378:metabolism; D014771:Virion / Q000378:metabolism; D053585:Virus Attachment; D000097573:Red Fluorescent Protein
D036022:Capsid Proteins; D004274:DNA, Recombinant; D008164:Luminescent Proteins; D011107:Polylysine; D013937:Thymidine Kinase; D000097573:Red Fluorescent Protein; C018315:hexon capsid protein, Adenovirus